贤丰控股(002141) - 2023 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2023 was ¥53,349,196.03, a decrease of 91.09% compared to ¥598,439,372.45 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥20,783,669.20, representing a decline of 188.87% from a profit of ¥23,387,289.92 in the previous year[19]. - The net cash flow from operating activities was -¥38,296,134.46, which is a 44.02% increase in cash outflow compared to -¥26,590,990.28 in the same period last year[19]. - The basic earnings per share were -¥0.0183, down 188.83% from ¥0.0206 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was -¥33,923,806.97, a slight increase in loss of 1.83% compared to -¥33,314,762.23 in the previous year[19]. - The company reported a significant shift in its revenue structure, with biological products accounting for 81.03% of total revenue at ¥43,227,119.62, up 48.26% year-on-year[37]. - The company reported a net loss of CNY 206,982,170.38 as of June 30, 2023, compared to a loss of CNY 186,188,290.85 at the beginning of the year[121]. - The total comprehensive income for the first half of 2023 was -7,270,773.24 CNY, compared to 96,785,532.94 CNY in the same period of 2022, indicating a substantial decline in overall financial performance[134]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,296,395,708.57, a decrease of 3.49% from ¥1,343,332,102.28 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were ¥1,136,658,701.30, down 0.82% from ¥1,146,062,191.42 at the end of the previous year[19]. - Cash and cash equivalents decreased to ¥77,721,087.28, representing 6.00% of total assets, down from 16.53% last year, a decrease of 10.53%[42]. - Total liabilities decreased from CNY 124,403,793.49 to CNY 89,485,459.74, a reduction of approximately 28.1%[121]. - The company's equity attributable to shareholders decreased from CNY 1,146,062,191.42 to CNY 1,136,658,701.30, a decline of about 0.8%[121]. Research and Development - The company has increased its R&D personnel significantly, particularly in cutting-edge technology and product development, including the recruitment of a chief scientist[30]. - Research and development expenses decreased by 69.99% to ¥7,403,817.69 from ¥24,673,458.50 in the previous year[35]. - The company is investing in new technologies and product development to comply with evolving regulatory standards in the veterinary biological products sector[59]. Market and Competition - The company’s veterinary vaccine business is closely tied to the pig farming industry, which has faced a continuous decline in pig prices for 8 months, leading to intensified price competition in the veterinary vaccine sector[27]. - The company reported a decrease in gross profit margins due to the ongoing downturn in the pig farming industry and increased competition[27]. - The veterinary biological products industry is experiencing high competition, and the company is focusing on enhancing its market risk management strategies[58]. Environmental Responsibility - The company has established an emergency response plan for environmental incidents, valid from July 2022 to July 2025[69]. - The company has implemented low-nitrogen burners in its gas boiler to reduce nitrogen oxide emissions[69]. - The company has a commitment to corporate social responsibility, focusing on environmental protection and stakeholder rights[70]. Corporate Governance - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[3]. - The company has maintained a good relationship with suppliers and actively works on customer satisfaction improvement[71]. - There were no significant lawsuits or arbitration matters during the reporting period[80]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 44,802[107]. - Guangdong Xianfeng Holdings Co., Ltd. holds 26.03% of the shares, totaling 295,358,647 ordinary shares, which are pledged[107]. - The company has not issued any new shares or conducted any share repurchase during the reporting period[105]. Financial Management - The total amount of entrusted financial management is 81 million RMB, with an unexpired balance of 54.06 million RMB[96]. - The company has no overdue amounts for entrusted financial management products, indicating a strong liquidity position[96]. - The company has not reported any high-risk entrusted financial management situations, indicating a cautious investment approach[98]. Accounting Policies - The financial statements are prepared based on the actual transactions and events in accordance with the accounting standards issued by the Ministry of Finance[163]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[164]. - The accounting policies and estimates are tailored to the characteristics of the company's main business of animal health vaccines[165].